Inhibitors of the renin-angiotensin system remain a cornerstone of cardiovascular pharmacotherapy. Although angiotensin converting enzyme inhibitors (ACEIs) have been demonstrated to afford cardiovascular risk reduction in patients with atherosclerosis and preserved left ventricular function, at the present time it is unclear if angiotensin receptor blockers (ARBs) exert similar benefits. We pe...

Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as severe acute respiratory syndrome 2 (SARS-CoV-2) has triggered global pandemic affecting billions lives and posing stiff challenge to the delivery routine healthcare across world. The new second wave COVID-19 in India presents with higher rate infection percentage asymptomatic mildly symptomatic cases is much than b...

0

BACKGROUND The continued use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II subtype I receptor antagonists (ARBs) medications in the preoperative period has been reported to be associated with intraoperative hypotension that can be unresponsive to pressor drugs. As a result, several investigators suggested discontinuation of these medications before scheduled surgery but...

Contrast-induced nephropathy (CIN) is associated with increased morbidity and mortality in patients undergoing diagnostic procedures and/or interventional procedures in the cardiac catheterization laboratory. Angiotensin-converting enzyme inhibitor (ACEI) use has been implicated both as increasing the risk of developing CIN and as a protective factor against developing CIN. Because many patient...

The impact of heart failure (HF) on acute myocardial infarction (AMI) in patients from southwestern China remains unclear. The present study aimed to compare in-hospital cardiovascular events, mortality and clinical therapies in AMI patients with or without HF in southwestern China. In total, 591 patients with AMI hospitalized between February 2009 and December 2012 were examined; those with a ...

BACKGROUND Studies have examined the use of evidence-based therapies for coronary artery disease (CAD) in the short term and at hospital discharge, but few have evaluated long-term use. METHODS AND RESULTS Using the Duke Databank for Cardiovascular Disease for the years 1995 to 2002, we determined the annual prevalence and consistency of self-reported use of aspirin, beta-blockers, lipid-lowe...

background: there is controversy over the potential benefits/harms of the usage of angiotensin-converting enzyme inhibitors (aceis) or angiotensin receptor blockers (arbs) as regards the postoperative mortality of coronary artery bypass grafting (cabg). this study investigates the correlation between the in-hospital mortality of cabg and the preoperative administration of acei/arb. methods: out...

Since its discovery in the late 19th century, our may limit the degree of RAAS suppression that is conceptual understanding of the renin-angiotensin-aldosterone system (RAAS) has undergone a process of continuous evolution. Renin was first described by Tigerstedt and Bergman, who, in 1898, documented pressor effects of tissue extracts from rabbit kidneys. Later investigators established that th...

Angiotensin-converting enzyme inhibitors (ACEIs) may have different effects on cardiac hypertrophy than on vascular hypertrophy. Arginine vasopressin (AVP) may promote cardiac hypertrophy. Our aims were (1) to simultaneously examine the chronic effects of ACEIs on hypertrophy of the heart and hypertrophy of the coronary and renal interlobular arteries, and (2) to clarify the relation between AV...